The key strategy for IHL is targeting conditions that do not have a pharmaceutical treatment option.
There are many conditions with a market opportunity that exceeds $1 Billion but most compete with existing (and often very successful) drugs. Clinical validation is important but if you are competing with an alternative drug that may also be PBS approved then the pathway to commercial success is prohibitive, and possibly impossible.
IHL are targeting conditions that have no pharmaceutical treatment option. The body of science and research expertise behind the clinical trials is second to none and these studies are being orchestrated by the most reputable name in the sector, Dr Sud Agarwal.
The previous 4 weeks have IMO flushed out all the short term traders and in my experience the buying has been professional money who understand the value proposition.
IHL Price at posting:
8.3¢ Sentiment: Buy Disclosure: Held
